GlassScriptPhysician profile
Rachael E Gross
NPI 1467438853
$3,753.55
in general payments reported to CMS, 2019-2025
34 companies · $555 in 2025
The $555 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $893 · 2021: $513 · 2022: $470 · 2023: $392 · 2024: $477 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,424.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $656.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $460.43 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Lilly USA, LLC | $305.65 | 2019-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $303.06 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $217.27 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $198.30 | 2019-2022 | |
| Glaxosmithkline, LLC. | $170.54 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.54 | 2019-2024 | Jardiance, Synjardy |
| Amgen INC. | $135.83 | 2019-2025 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $130.38 | 2020-2023 | Verquvo, Belsomra |
| Corcept Therapeutics | $113.50 | 2024-2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.05 | 2022-2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $76.40 | 2020-2022 | |
| Ardelyx, INC. | $72.92 | 2024-2025 | Ibsrela |
| Kowa Pharmaceuticals America, INC. | $65.57 | 2021-2025 | Zoryve |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $64.65 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.57 | 2020-2021 | |
| Exact Sciences Corporation | $47.94 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $46.18 | 2022 | |
| Eisai INC. | $44.48 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $43.59 | 2022-2023 | Abilify Maintena, Rexulti |
| Pfizer INC. | $42.60 | 2019-2024 | |
| Allergan, INC. | $42.37 | 2020 | |
| Mylan Specialty L.P. | $35.82 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $28.48 | 2019 | |
| Dexcom, INC. | $23.50 | 2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $20.22 | 2025 | Gvoke Hypopen |
| Arbor Pharmaceuticals, INC. | $18.49 | 2021 | |
| Astellas Pharma US INC | $15.99 | 2023 | Veozah |
| Edwards Lifesciences Corporation | $15.89 | 2021 | |
| Neos Therapeutics, LP | $15.12 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.64 | 2019 | |
| Hikma Pharmaceuticals USA | $12.93 | 2020 | |
| Alnylam Pharmaceuticals INC. | $12.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachael Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.